leadf
logo-loader
viewFutura Medical PLC

Futura Medical submits MED3000 for European approval, US wants new confirmatory trial

Approval is being sought for MED3000 to be sold over-the-counter without a prescription

Futura Medical PLC -

Futura Medical PLC (LON:FUM) said it had submitted the product dossier for its treatment of erectile dysfunction known as MED3000 for marketing approval in Europe.

A further update on MED3000's EU regulatory approval will be made alongside its interim results in September and the target remains a 2021 approval date, it added.

WATCH: Futura Medical's Ken James updates on EU and US regulatory progress for MED3000

In the US, Futura said that after a second pre-submission meeting with the US Food and Drug Administration (FDA), a pathway to US marketing approval for MED3000 has been established.

Importantly, this will be without the need for a doctor's prescription, Futura added, so MED3000 will be sold over-the-counter alongside other leading treatments for erectile dysfunction such as Viagra and Cialis, which are also sold without prescription.

The FDA also indicated a requirement for certain additional clinical efficacy data beyond the company's three months' home use study conducted in 2019 in 1,000 patients suffering from mild, moderate and severe ED ("FM57"). 

This additional data will require a further small clinical trial, said Futura, where patients with erectile problems will receive MED3000 for a six-month treatment period. 

"Confirmatory studies such as this generally require low subject numbers and is likely to be significantly smaller in size than FM57," said Futura.

Next steps will be to confirm design of the new clinical trial with the FDA to provide the necessary reassurance of MED3000's efficacy for up to six months, it added, and progress the OTC label and leaflet development.

James Barder, Chief Executive of Futura Medical commented: "Futura is executing and delivering against strategic plans. We are pleased to have now submitted MED3000 for European approval as a clinically proven treatment for ED. 

“Once granted, EU approval will allow MED3000 to be marketed throughout the EU without the need of a doctor's prescription subject to any national marketing restrictions.  This represents a significant commercial opportunity."

Quick facts: Futura Medical PLC

Price: 14.25 GBX

AIM:FUM
Market: AIM
Market Cap: £35 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Futura Medical PLC named herein, including the promotion by the Company of Futura Medical PLC in any Content on the Site, the Company receives...

FOR OUR FULL DISCLAIMER CLICK HERE

Futura Medical kicks off work on Phase III trial for erectile dysfunction gel

James Barder, chief executive of Futura Medical PLC (LON:FUM), tells Proactive they've begun preparatory work on the first Phase III efficacy trial for MED2002 - their topical gel for erectile dysfunction (ED). The study will recruit approximately 1,000 patients with mild, moderate and...

on 27/4/18

2 min read